All In Biotech

NDA 219015 · Journey

Emrosi

Minocycline Hydrochloride · Oral

Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Nov 1, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

291

55 Phase 3, 18 recruiting

FAERS reports

18

4 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 22, 2025.

EMROSI is indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults. Limitations of Use This formulation of minocycline has not been evaluated in the treatment or prevention of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, use EMROSI only as indicated. EMROSI is a tetracycline-class drug indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults. ( 1 ) Limitations of Use This formulation of minocycline has not been evaluated in the treatment or prevention of infections. To reduce the development of drug-resistant bacteria and to maintain the effectiveness of other antibacterial drugs, use EMROSI only as indicated. ( 1 )

Mechanism: The mechanism of action of EMROSI for the treatment of rosacea is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 1, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • EMROSI · MINOCYCLINE HYDROCHLORIDE EQ 40MG BASE · CAPSULE, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Minocycline" as an intervention, any sponsor and status, largest first.

All 291 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness4
  • rash4
  • back pain2
  • gastrointestinal disorder2
  • headache2
  • product use in unapproved indication2
  • pruritus2
  • anaemia1
  • arthralgia1
  • burning sensation1
  • condition aggravated1
  • diarrhoea1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20258
202610

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 690 on PubMed

Sponsor: Journey

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.